JPWO2021129653A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021129653A5 JPWO2021129653A5 JP2022539058A JP2022539058A JPWO2021129653A5 JP WO2021129653 A5 JPWO2021129653 A5 JP WO2021129653A5 JP 2022539058 A JP2022539058 A JP 2022539058A JP 2022539058 A JP2022539058 A JP 2022539058A JP WO2021129653 A5 JPWO2021129653 A5 JP WO2021129653A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- compound according
- optical isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 28
- 230000003287 optical effect Effects 0.000 claims 23
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052740 iodine Inorganic materials 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000004455 (C1-C3) alkylthio group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911342649.0 | 2019-12-23 | ||
| CN201911342649 | 2019-12-23 | ||
| CN202010200682.6 | 2020-03-20 | ||
| CN202010200682 | 2020-03-20 | ||
| CN202010496353 | 2020-06-03 | ||
| CN202010496353.0 | 2020-06-03 | ||
| CN202011486334.6 | 2020-12-16 | ||
| CN202011486334 | 2020-12-16 | ||
| PCT/CN2020/138572 WO2021129653A1 (zh) | 2019-12-23 | 2020-12-23 | 一种蛋白降解剂化合物的制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023508097A JP2023508097A (ja) | 2023-02-28 |
| JPWO2021129653A5 true JPWO2021129653A5 (ko) | 2024-01-09 |
Family
ID=76573691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539058A Pending JP2023508097A (ja) | 2019-12-23 | 2020-12-23 | タンパク質分解剤化合物の製造方法及び使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230111119A1 (ko) |
| EP (1) | EP4083020A4 (ko) |
| JP (1) | JP2023508097A (ko) |
| KR (1) | KR20220120629A (ko) |
| CN (2) | CN114829342A (ko) |
| AU (1) | AU2020414151A1 (ko) |
| BR (1) | BR112022012385A2 (ko) |
| CA (1) | CA3162523A1 (ko) |
| CL (1) | CL2022001724A1 (ko) |
| CO (1) | CO2022010305A2 (ko) |
| EC (1) | ECSP22056811A (ko) |
| IL (1) | IL294225A (ko) |
| JO (1) | JOP20220159A1 (ko) |
| MX (1) | MX2022007885A (ko) |
| PE (1) | PE20230114A1 (ko) |
| TW (1) | TWI755992B (ko) |
| WO (1) | WO2021129653A1 (ko) |
| ZA (1) | ZA202208051B (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118638043A (zh) | 2019-12-19 | 2024-09-13 | 阿尔维纳斯运营股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| EP4146642A1 (en) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| CN113801098B (zh) | 2020-06-12 | 2023-05-30 | 上海济煜医药科技有限公司 | 酞嗪酮类化合物及其制备方法和医药用途 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| EP4367112A1 (en) | 2021-07-09 | 2024-05-15 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
| WO2024002289A1 (en) * | 2022-06-30 | 2024-01-04 | Anhorn Medicines Co., Ltd. | Protein degradation compounds and methods of use |
| WO2024012570A1 (zh) * | 2022-07-15 | 2024-01-18 | 西藏海思科制药有限公司 | 一种含氮杂环衍生物及其组合物和药学上的应用 |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) * | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| CN107428734A (zh) * | 2015-01-20 | 2017-12-01 | 阿尔维纳斯股份有限公司 | 用于雄激素受体的靶向降解的化合物和方法 |
| KR102173463B1 (ko) * | 2016-10-11 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 안드로겐 수용체의 표적 분해용 화합물 및 방법 |
| CA3042301A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use |
| WO2018098275A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
-
2020
- 2020-12-23 IL IL294225A patent/IL294225A/en unknown
- 2020-12-23 AU AU2020414151A patent/AU2020414151A1/en active Pending
- 2020-12-23 KR KR1020227025429A patent/KR20220120629A/ko active Search and Examination
- 2020-12-23 EP EP20908128.0A patent/EP4083020A4/en active Pending
- 2020-12-23 MX MX2022007885A patent/MX2022007885A/es unknown
- 2020-12-23 JO JOP/2022/0159A patent/JOP20220159A1/ar unknown
- 2020-12-23 PE PE2022001313A patent/PE20230114A1/es unknown
- 2020-12-23 CA CA3162523A patent/CA3162523A1/en active Pending
- 2020-12-23 CN CN202080087926.2A patent/CN114829342A/zh active Pending
- 2020-12-23 WO PCT/CN2020/138572 patent/WO2021129653A1/zh active Application Filing
- 2020-12-23 CN CN202011545626.2A patent/CN113087704B/zh active Active
- 2020-12-23 US US17/788,154 patent/US20230111119A1/en active Pending
- 2020-12-23 TW TW109145818A patent/TWI755992B/zh active
- 2020-12-23 BR BR112022012385A patent/BR112022012385A2/pt unknown
- 2020-12-23 JP JP2022539058A patent/JP2023508097A/ja active Pending
-
2022
- 2022-06-22 CL CL2022001724A patent/CL2022001724A1/es unknown
- 2022-07-19 ZA ZA2022/08051A patent/ZA202208051B/en unknown
- 2022-07-20 EC ECSENADI202256811A patent/ECSP22056811A/es unknown
- 2022-07-21 CO CONC2022/0010305A patent/CO2022010305A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020023528A5 (ko) | ||
| JP2016518437A5 (ko) | ||
| JP6892381B2 (ja) | 多発性骨髄腫を治療するための薬物の組み合わせ | |
| JP2005536475A5 (ko) | ||
| JP2008534453A5 (ko) | ||
| JP2007507494A5 (ko) | ||
| JP2020534264A5 (ko) | ||
| JP2003520195A5 (ko) | ||
| JP2004517843A5 (ko) | ||
| JP2016522254A5 (ko) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2019521988A5 (ko) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015535247A5 (ko) | ||
| JPWO2021129653A5 (ko) | ||
| JPWO2022014639A5 (ko) | ||
| HUP0302306A2 (hu) | PPAR-alfa aktiváló propionsavszármazékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| RU2004103475A (ru) | Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи | |
| JPWO2021249534A5 (ko) | ||
| JP2008520611A5 (ko) | ||
| RU2010141578A (ru) | Производные (пиразолилкарбонил)имидазолидинона, предназначенные для лечения ретровирусных заболеваний | |
| RU2018127494A (ru) | Химические соединения в качестве ингибиторов киназной активности | |
| JP2004534818A5 (ko) | ||
| JP2021503451A5 (ko) | ||
| JP2021504384A5 (ko) |